USE OF RIFAPENTINE IN THE TREATMENT OF TUBERCULOSIS IN PATIENTS INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) / ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) AND TREATED WITH AN ANTIRETROVIRAL COMBINATION

摘要

The invention relates to new doses and regimens of rifapentine and use in the treatment of active tuberculosis disease or tuberculosis infection in patients infected with the human immunodeficiency virus (HIV) / acquired immune deficiency syndrome (AIDS) and treated with a combined antiretroviral combination, in particular with an efavirenz-based combination, and more particularly with a combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate.